|
2011 BIO promises Russia good bio-tech prospects
01.07.2011 10:15 "Agro Perspectiva" (Kyiv) —
On June 2730, Washington hosted the 2011 BIO International Convention. BIO is the world leading conference of bio-tech industries and is often called «bio-technological Davos». Traditionally it focuses on three industries - pharmaceutical industry, medical technologies and healthcare. This year it was attended by 15,000 people from 65 countries.
Though Russia has been the convention’s participant for 20 years, only this year it opened its own pavilion at this forum. Time is ripe to declare itself not only as the seller but also as a producer and developer, Evgeny Kuznetsov, the head of the development and communications department of the Russian venture company says.
«I liked the very fact that Russia has been given a venue to learn about the situation in the field of pharmaceutical industry and bio-technologies and to discuss options for partnership. Our bio- tech and pharmaceutical companies are going through a breaking point when business development models are changing. Big companies are showing interest in new know-how and new sources of know-how. This is an advantage for Russia, which traditionally was strong in fundamental science and some companies already learnt how to fit into the current global processes. This potential should be developed further. I think Russia has good prospects.»
The format of the forum does not imply signing of contracts. This is the venue for communication for meeting with potential partners but as a rule in the end of such meetings all the participants have concrete plans of cooperation, Igor Goryanin, the head of the department of bio- medical technologies at the Skolkovo Innovative center, says.
«We plan to conduct joint research in our department of bio and medical technologies together with the US companies, involving the Russian universities, the Academy of Medical Sciences, Russian pharmaceutical companies. We expect the US companies to come to Skolkovo and create their research centers there which will contribute to higher quality of bio-tech research. We hope it will also help to bring new Russian medicines and new methods of diagnostics to the market.»
The first results have already been achieved. On the sidelines of the 2011 BIO forum the Russian KhimRar center of high-technologies and the US Pfizer pharmaceutical company have signed a memorandum of understanding. The representatives of the two companies told us that the cooperation will imply brining Pfizer products to the Russian market and the joint research and elaboration of new technologies.
Also available:
|
| |
|
|